Insmed to Report Top-Line Results From Phase 3 Clinical Trial of ARIKACE to Treat Pseudomonas Aeruginosa in Cystic Fibrosis
Conference Call Scheduled for Monday, July 1, 2013 at 8:00 a.m. Eastern Time
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 06/28/13 -- Insmed Incorporated (NASDAQ: INSM), ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients battling serious lung diseases that are often life-threatening, today announced that the Company will report top-line results from its European and Canadian Phase 3 study of ARIKACE® (liposomal amikacin for inhalation) to treat cystic fibrosis patients with Pseudomonas aeruginosa lung infections on Monday, July 1, 2013 at 7:00 a.m. Eastern time.
Just noticed that the header states the time of the call on Mionday as 8:00 AM ET, but in the body of the PR, it states 7:00 AM ET. At least the dates match, sheesh. IR is gone for the day, or they did not answer the phone.